secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001493152-24-049994
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma appoints Rahul Singhvi as director, replacing Rosemary Mazanet
----------------------------------------------------------------------------

- Dr. Rosemary Mazanet resigned from board effective upon appointment of new independent director; not due to disagreement.
- Dr. Rahul Singhvi appointed director effective Dec 10, 2024; will serve on audit committee, chair compensation and nominating/corporate governance committees.
- Singhvi is cofounder of Resilience, former CEO of Novavax (NVAX), former COO of Takeda's Vaccine business.
- Singhvi receives $50K annual cash fee and $50K in RSUs vesting over three years under 2023 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224049994/0001493152-24-049994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224049994/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-049994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer